Nurix Therapeutics (NRIX) Accounts Payables (2019 - 2026)

Nurix Therapeutics (NRIX) has reported Accounts Payables for 8 consecutive years, with $12.2 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Accounts Payables rose 105.04% year-over-year to $12.2 million; the TTM figure through May 2026 stood at $12.2 million (up 105.04% YoY), while the FY2025 annual figure was $11.2 million, down 2.33% from the prior year.
• Accounts Payables grew to $12.2 million in Q2 2026 per NRIX's latest filing, from $10.3 million in the prior quarter.
• Across five years, Accounts Payables topped out at $12.2 million in Q2 2026 and bottomed at $2.2 million in Q3 2023.
• Historically, Accounts Payables has averaged $6.8 million across 5 years, with a median of $6.0 million in 2022.
• Annual changes were most pronounced in 2023 — Accounts Payables tumbled 63.87% — and 2025, when it jumped 119.73%.
• Nurix Therapeutics' Accounts Payables stood at $5.1 million in 2022, then climbed by 26.4% to $6.4 million in 2023, then soared by 79.38% to $11.5 million in 2024, then declined by 2.33% to $11.2 million in 2025, then grew by 8.85% to $12.2 million in 2026.
• Business Quant data shows NRIX's Accounts Payables at $12.2 million in Q2 2026, $10.3 million in Q1 2026, and $11.2 million in Q4 2025.